• A Company Dedicated to Safe Therapeutic Modulation of Monoamine Neurotransmitter

    Read more

  • Annual report 2022

    Read the report

  • Reports positive statistically significant and clinically relevant Phase IIb efficacy data with pudafensin

    Read the press release

  • Interim Report January – September 2023

    Read the report

Press releases

Older releases

Latest reports

All reports

Calendar

All events

Share

Read more

Initiator Pharma Numbers

  • Expected Number of men affected by Erectile Dysfunction worldwide by 2025 322 million
  • Number of people worldwide that are diagnosed with Trigeminal Neuralgia every year: 15000
  • Men with Erectile Dysfunction who do not respond to drug therapy 40 %
Initiatorpharma-module-homepage-1-22102021

Initiator Pharma currently has a portfolio of five projects, of which three are in clinical development and two are in preclinical development.

View our Pipeline

CEO letter

2023 has so far been an exciting and stimulating year for Initiator Pharma, where we have achieved multiple important milestones across our development pipeline. Our most important milestone, the positive statistically significant and clinically relevant efficacy data with pudafensine from the completed Phase IIb trial in psychogenic ED, was announced just after the end of the period.

Read the full letter
Initiatorpharma-module-homepage-2-22102021

Monoamine transporters is a unique class of proteins that are located just outside the synaptic cleft (peri-synaptically), transporting monoamine transmitter overflow from the synaptic cleft back to the cytoplasm of the pre-synaptic neuron. Our unique monoamine reupdate inhibitors are targeting the monoamine transporters to increase the levels of monoamine transmitters in diseases.

Read more about our technology